Toxicity Studies of Cardiac-Targeting Peptide Reveal a Robust Safety Profile

Area of Science:

• Cardiovascular Research
• Drug Delivery Systems
• Toxicology

Background:

• Targeted delivery to cardiomyocytes is crucial for treating heart failure.
• A cardiac-targeting peptide (CTP) was previously identified for selective cardiomyocyte delivery.
• CTP has been utilized for delivering various agents, including imaging agents and therapeutics.

Purpose of the Study:

• To evaluate the in vitro and in vivo toxicity of the cardiac-targeting peptide (CTP).
• To assess the safety profile of CTP for potential clinical application as a cardiac vector.

Main Methods:

• In vitro cytotoxicity assays on human cardiomyocytes and ion channel profiling.
• In vivo studies including blood pressure monitoring, complete blood count, metabolic profiling, and organ-specific toxicity assessments in mice.
• Cardiac MRI to evaluate cardiac function and dimensions post-CTP administration.

Main Results:

• No significant decrease in cardiomyocyte viability was observed in vitro.
• No significant activation or inhibition of tested protein channels, except OPRM1 and COX2 (not expressed in mouse heart).
• In vivo studies revealed no significant hematological, hepatic, renal, or thyroid toxicities, and no adverse effects on cardiac function or blood pressure.

Conclusions:

• The cardiac-targeting peptide (CTP) exhibits a favorable safety profile with no significant in vitro or in vivo toxicity.
• CTP does not adversely affect cardiac function, size, or blood pressure.
• Further long-term, good laboratory practice studies are warranted before human clinical trials.